- Home
- SHOO vs SUPN Comparison
SHOO vs SUPN Comparison
Compare SHOO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- SUPN
- Stock Information
- Founded
- SHOO 1990
- SUPN 2005
- Country
- SHOO United States
- SUPN United States
- Employees
- SHOO N/A
- SUPN N/A
- Industry
- SHOO Shoe Manufacturing
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- SHOO Consumer Discretionary
- SUPN Health Care
- Exchange
- SHOO Nasdaq
- SUPN Nasdaq
- Market Cap
- SHOO 2.5B
- SUPN 2.6B
- IPO Year
- SHOO 1993
- SUPN 2012
- Fundamental
- Price
- SHOO $37.08
- SUPN $44.75
- Analyst Decision
- SHOO Buy
- SUPN Strong Buy
- Analyst Count
- SHOO 8
- SUPN 4
- Target Price
- SHOO $40.00
- SUPN $63.25
- AVG Volume (30 Days)
- SHOO 1.4M
- SUPN 1.1M
- Earning Date
- SHOO 11-05-2025
- SUPN 11-04-2025
- Dividend Yield
- SHOO 2.25%
- SUPN N/A
- EPS Growth
- SHOO N/A
- SUPN N/A
- EPS
- SHOO 0.78
- SUPN N/A
- Revenue
- SHOO $2,362,727,000.00
- SUPN $681,539,000.00
- Revenue This Year
- SHOO $11.74
- SUPN $8.29
- Revenue Next Year
- SHOO $10.47
- SUPN $22.72
- P/E Ratio
- SHOO $47.86
- SUPN N/A
- Revenue Growth
- SHOO 6.41
- SUPN 4.54
- 52 Week Low
- SHOO $19.05
- SUPN $29.16
- 52 Week High
- SHOO $46.76
- SUPN $57.65
- Technical
- Relative Strength Index (RSI)
- SHOO 57.57
- SUPN 38.55
- Support Level
- SHOO $32.25
- SUPN $44.22
- Resistance Level
- SHOO $39.86
- SUPN $45.96
- Average True Range (ATR)
- SHOO 1.55
- SUPN 2.46
- MACD
- SHOO 0.00
- SUPN -0.86
- Stochastic Oscillator
- SHOO 66.75
- SUPN 14.92
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.